# A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

> clinical trial · VERIFIED · 2026-07-31

Status: RECRUITING · Sponsor: Janssen Research & Development, LLC · Condition: Carcinoma, Non-Small-Cell Lung

- Company: Janssen Research & Development, LLC
- Sector: Carcinoma, Non-Small-Cell Lung
- Primary source: https://clinicaltrials.gov/study/NCT07586202

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.